Business Context and Reporting Period
AtriCure, Inc. is a medical device company specializing in cardiac surgical ablation systems designed to treat atrial fibrillation (AF). The primary product is the Isolator® bipolar ablation system, used to create lesions in cardiac tissue. The company operates in a single segment with sales primarily in the United States (86% of 2007 revenue) and internationally (14%).
Reporting Period: Fiscal year ended December 31, 2007.
Key Operational Note: While the FDA cleared the Isolator system for cardiac tissue ablation in July 2007, the company cannot market the product specifically for the treatment of AF until FDA approval is obtained. Substantially all revenues are currently generated through off-label use by physicians.
Key Financial Metrics
| Metric | 2007 | 2006 |
|---|---|---|
| Revenues | $48.3 million | $38.2 million |
| Gross Profit | $38.2 million | $30.6 million |
| Gross Margin | 79.0% | 80.1% |
| Net Loss | $(11.3) million | $(13.7) million |
| Loss Per Share (Basic/Diluted) | $(0.84) | $(1.13) |
| Cash, Cash Equivalents & Short-Term Investments | $20.0 million | $19.5 million |
| Working Capital | $24.6 million | $23.0 million |
| Total Debt (Current & Long-Term) | $1.1 million | $1.1 million |
| Accumulated Deficit | $(67.3) million | $(56.1) million |
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased 26.3% to $48.3 million, driven by a 36% increase in unit sales. This was partially offset by a decrease in worldwide average selling prices due to a higher mix of international sales (which utilize distributors) and product mix changes.
- Operating Expenses: Total operating expenses increased to $50.7 million (105.0% of revenue) from $45.4 million (118.7% of revenue).
- Selling, General & Administrative (SG&A): Increased $6.6 million, primarily due to headcount growth ($4.8 million), marketing expenditures ($1.0 million), and stock option expense ($0.8 million).
- Research & Development (R&D): Decreased $1.2 million to $11.0 million, attributed to reduced external product development expenses and redeployment of clinical staff to sales roles.
- Profitability: The net loss narrowed by $2.5 million to $11.3 million, despite continued operating losses, due to improved gross margins and reduced R&D spend.
- Acquisitions: In August 2007, the company acquired the Frigitronics® CCS-200 cardiac cryoablation product line for $3.7 million, adding $2.9 million in goodwill.
Guidance, Outlook, and Risks
Outlook and Product Pipeline:
- ABLATE Trial: The company is conducting a pivotal clinical trial (ABLATE) to evaluate the Isolator system for permanent AF during open-heart procedures. If successful, the company intends to seek FDA approval as early as 2010.
- New Products: Plans to introduce the Coolrail™ Linear Ablation Pen (H1 2008), a disposable cryoablation probe (H2 2008), and the Left Atrial Appendage Exclusion System (expected clearance H2 2008 or 2009).
- Liquidity: Management believes current cash and cash equivalents ($20.0 million) are sufficient to meet capital requirements for at least the next 12 months.
Material Risks and Contingencies:
- Regulatory Risk: The company cannot promote its products for the treatment of AF without FDA approval. Failure to obtain approval could halt sales or require significant financing for additional trials.
- Reimbursement: Changes in Medicare CPT codes in 2007 negatively impacted reimbursement for open-heart concomitant procedures, though new codes effective January 2008 are expected to improve this.
- Legal Proceedings: The company is a defendant in a securities class action lawsuit regarding its 2005 IPO. The company intends to defend vigorously but notes potential costs and management distraction.
- Off-Label Promotion: There is a risk of regulatory enforcement if the company is deemed to be promoting products for non-FDA-approved uses.
Investor Verification Checklist
- FDA Approval Timeline: Verify the progress of the ABLATE clinical trial and the likelihood of obtaining FDA approval for AF treatment by 2010.
- Reimbursement Impact: Assess the actual impact of the new 2008 CPT codes on physician reimbursement and subsequent demand for open-heart products.
- Off-Label Sales Sustainability: Evaluate the risk that regulatory actions regarding off-label promotion could restrict current revenue streams.
- Capital Requirements: Confirm that the $20 million cash position is sufficient to fund operations and clinical trials without dilutive equity raises in the near term.
- Legal Exposure: Monitor the status of the securities class action lawsuit and potential indemnification costs.